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tion. The cohort of new births, indicative of interventions’
impact, had signiﬁcantly lower mean ages at administra-
tion for DPT 2 and DPT 3 (p < 0.0001). Statistically signiﬁcant
trend in decline was observed for mean age at DPT 1, DPT
2 and DPT 3 from ﬁrst to sixth quarter of study period
(p < 0.0001).
Conclusion: Better programme management can improve
performance levels. Community volunteers can increase
outreach services. Government of India’s recent health sec-
tor reforms of decentralization which provide ﬂexibility
at the district level and below to hire contractual staff
and introduction of community volunteer called Accred-
ited Social Health Activists (ASHA) under the National Rural
Health Mission (NRHM) is likely to strengthen immunization
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Background: Inﬂuenza vaccines are currently produced
using embryonated chicken-eggs for inﬂuenza virus prop-
agation. Mammalian cell cultures have been employed as
an alternative technology, primarily to overcome some lim-
itations of current inﬂuenza vaccine manufacture from
embryonated eggs. This study aimed to evaluate the safety
and tolerability of a new cell culture-derived trivalent
inactivated inﬂuenza vaccine (CCIV) (OPTAFLU®, Novartis
Vaccines), produced using Madin-Darby canine kidney cell
culture, and demonstrate its immunological non-inferiority
to an egg-based trivalent inactivated inﬂuenza vaccine (TIV)
(Agrippal S1®, Novartis Vaccines).
Methods: In a Phase III study, 1300 adult (18—60 years
of age) and 1354 elderly (≥61 years of age) subjects were
randomized (1:1) to receive one dose of either CCIV or
TIV. Solicited local and systemic reactions within 7 days,
all adverse events (AE) up to Day 22, and all serious
AE and AE leading to withdrawal up to 6 months were
evaluated. Immunogenicity was assessed 3 weeks after
vaccination, in compliance with European Committee for
Medicinal Products for Human Use (CHMP) criteria, using the
hemagglutination-inhibition (HI) assay.
Results: Solicited local or systemic reactions experienced
in both vaccine groups were mostly mild or moderate in
severity. There were no differences in the immune responses
induced by either of the two vaccines for each of three
inﬂuenza strains (A/H1N1, A/H3N2 and B). In adults, post-
vaccination seroprotection rates (HI titer ≥40 IU) were
90—99% and 91—99% for CCIV and TIV groups, respectively. In
elderly subjects, post-vaccination seroprotection rates were
85—97% and 85—98% for CCIV and TIV groups, respectively.
Both vaccines met all three CHMP criteria in both age groups
and the CCIV met predeﬁned criteria for non-inferiority.
Conclusion: The CCIV was as safe and well tolerated as
the TIV, and was immunologically non-inferior to the TIV.
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The ﬁrst recorded major outbreak of Japanese Encephali-
tis (JE) in Sri Lanka occurred in 1985—86 with 385 cases and
64 deaths in the North Central province. Outbreaks occurred
in 1986—87, 1987—88, the latter being the largest with 812
cases and 192 deaths with the spread to three adjoining
districts. The affected were rice cultivating areas with a
network of irrigation canals supported by seasonal, moder-
ate to heavy rainfall. Children in the age group 5—9 and
young adults in 20—24 years were predominantly affected.
Though JE was prevalent in endemic districts, it was
spreading to newer areas of previous low transmission. To
cope with this emerging challenge, immunization against JE
was initiated on phase basis in 1988. Children aged 1—10
years were offered three primary doses and a booster of
inactivated vaccine in the interpandemic period in a cam-
paign approach. Over the years, immunisation coverage
increased with the reduction of JE incidence. However, cases
and occasional outbreaks were reported in other districts
where immunization was not carried out resulting in exten-
sion of the immunization to 18 districts.
Simultaneously, there was an increasing trend of adverse
events following JE vaccine partly attributable to the change
of the product with possible adverse repercussions on the
JE immunization programme. The other obstacle was the
increasing cost of the inactivated vaccine which amounted
to US$4.50 per a dose in 2006. The high vaccine cost was
a prohibitive factor to sustain the programme of JE immu-
nization. Therefore, an affordable, safe and immunogenic
vaccine alternative was a high priority.
Against this background, live JE vaccine (LJEV) SA 14-14-
2 appeared to be an appropriate, low cost, safe and potent
alternative. To ascertain the safety and immunogenicity of
LJEV, with the support of the PATH in 2007, a clinical trial
was conducted by the Epidemiology Unit. Based on pre-
liminary results of the trial, Sri Lanka has now decided to
introduce LJEV in place of the inactivated vaccine to the
JE Immunization Programme and hopefully to the EPI very
soon.
Currently, the Ministry of Health is negotiating to receive
a public price for procurement of JELV. Details of the sug-
gested schedule are yet to be decided. However, cost savings
from LJEV will enable the introduction of beneﬁts of new
vaccines to Sri Lankan children and, on an optimistic note,
LJEV to adults in high endemic areas in the future.
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